Fractyl Health, Inc. Common Stock

NASDAQ:GUTS

Biotechnology

Healthcare
$4.16 -0.81%

-$0.01 today

Market cap
$55.18M
Beta
2.34
P/E (TTM)
-0.6
EPS (TTM)
-$1.42
52W Low $0.38High $2.45

Volume 0.10M

Average 2.07M

GUTS Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Fractyl Health, Inc. Common StockNASDAQ: GUTS

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash dips below year-ago levels

Q1 FY2026 net change in cash of $18.37M (cash outflow) fell 27.5% year over year, behind the +126.4% change in trailing-twelve-month net change in cash.

Context

  • Net change in cash increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -27.5% toward the trailing-twelve-month pace of +126.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$18.37M-573.1% QoQ
Last fiscal yearDec 2025
$14.08M-58.5% YoY
LTMMar 2026
$21.06M+126.4% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-27.5%——
1 year-58.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
14.08M USD
Year-over-year change
-58.5%
4-year CAGR
-32.1%

Net Change in Cash vs competitors

How GUTS compares with its peers on the latest reported figures

  • GUTS's LTM Mar 2026 net change in cash of $21.06M is the 3rd largest of the 7 companies compared; the peer median is $4.35M.
  • Its year-over-year change of +126.4% is the 2nd highest of 7, against a peer median of +15.6%.
GUTS Competitors Peer median
Net Change in Cash for GUTS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$32.55M -179.4%—32.7%
DTILPrecision BioSciences, Inc.LTM Mar 2026$22.28M +158.7%-14.5%49.4%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$21.06M +126.4%——
ALXOALX Oncology Holdings Inc.LTM Mar 2026$11.67M +77.5%-84.4%—
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$9.45M -46.3%-38.9%—
BMEABiomea Fusion, Inc.LTM Mar 2026$9.2M +108.4%-58.2%—
ATYRaTyr Pharma, Inc.LTM Mar 2026$504K -118.2%—265.3%
Peer median (excluding GUTS) $4.35M+15.6%-48.6%49.4%

Competitors are the stored peer set for GUTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(38.74M)(46.45M)(77.09M)(68.69M)(140.95M)
Depreciation & Amortization676K452K286K677K1.13M
Deferred Income Tax00000
Stock-Based Compensation2.09M3.14M4.3M14.43M6.68M
Change in Working Capital1.71M(1.24M)989K9.59M(395K)
Accounts Receivables00(22K)22K0
Inventory00(73K)073K
Accounts Payables666K0(427K)2.69M(1.67M)
Other Working Capital1.05M(1.24M)1.51M6.88M1.2M
Other Non-Cash Items795K(2.14M)28.7M(21.52M)43.21M
Operating Cash Flow(33.46M)(46.24M)(42.82M)(65.52M)(90.33M)
Capital Expenditures(51K)(56K)(359K)(1.77M)(557K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(51K)(56K)(359K)(1.77M)(557K)
Debt Repayment(7K)4.03M28.35M(187K)(457K)
Common Stock Issued0321K0103.7M105.42M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities40K0(911K)(2.28M)0
Financing Cash Flow99.88M4.35M27.44M101.23M104.96M
Effect of Forex Changes0(4.26M)000
Net Change in Cash66.37M(46.2M)(15.75M)33.94M14.08M
Free Cash Flow(33.51M)(46.3M)(43.18M)(67.29M)(90.89M)

Fractyl Health, Inc. Common Stock

NASDAQ:GUTS

Intrinsic Alpha fair value

Locked

Current Price

$4.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.